Articles tagged with Gpcr Pathway
Researchers at Duke University, University of Michigan, and Stanford University have determined the underlying architecture of a cellular signaling complex involved in responding to stimuli such as light and pain. The findings reveal a two-step mechanism that has been hypothesized previously but not directly documented.
Researchers solved the structure of the smoothened receptor, finding it has a similar shape to GPCRs despite low genetic similarity. This discovery provides insight into the role of SMO in cancer and embryonic development, potentially leading to new treatments for skin cancer and other diseases.
Researchers have determined the high-resolution atomic structures of two human serotonin receptor types, shedding light on why certain drugs interact with these receptors in complex and sometimes harmful ways. The study's findings offer valuable insights into designing safer and more effective medicines.
Researchers at VCU have discovered a new way to customize and target antipsychotic drugs to treat specific symptoms in psychosis patients. By targeting G-protein receptor complexes, they aim to reduce side effects and improve treatment outcomes.
A study by Nationwide Children's Hospital identified alpha arrestins as crucial regulators of G-protein coupled receptor signaling. Targeting these proteins could lead to more effective and side-effect-free drugs, potentially revolutionizing the pharmaceutical industry.
Researchers at Addex Pharmaceuticals have discovered a novel interaction between GLP-1 and GIP receptors, which has the potential to trigger new therapies for Type 2 diabetes. The discovery was made possible by the company's allosteric modulation platform and could lead to the development of orally available small molecule treatments.
Three international teams describe in unprecedented detail the workings of G protein-coupled receptors (GPCRs), a major molecular target for drugs. GPCRs are essential to human life, involved in almost every physiological function, and malfunctions have been linked to dozens of diseases.
The Penn team successfully grafted olfactory receptors onto carbon nanotubes, enabling the conversion of chemical signals into electrical signals. This technology has potential applications in pharmaceutical research and could help develop new treatments for diseases by targeting specific GPCRs.
Researchers from Scripps Research Institute determine a new structure of the human A2A adenosine receptor, bound to a full agonist, revealing a super stabilizing agonist. This finding has important implications for drug design, particularly for treating diseases such as Parkinson's and COPD.
Researchers have determined the structure of CXCR4, a protein that guides blood-forming stem cells, and its interactions with chemokine ligands. The findings may lead to new drugs for hematopoietic stem cell transplantation and treating HIV infection.
Researchers found that the level of arrestin protein determines how long C. elegans lives, with worms having triple the amount living one-third less than normal. Arrestin interacts with several proteins to regulate longevity and has relevance to human biology and cancer development.
Robert J. Lefkowitz, a leading expert on G-protein-coupled receptors, has been awarded the BBVA Foundation Frontiers of Knowledge Award for his groundbreaking research. His work has led to the development of millions of drugs used to treat various diseases worldwide.
Researchers at the University of Washington analyze PLC signal transmission process using fluorescence technology, extending kinetic model to cover entire signaling cascade. The studies reveal steps linking changes in PtdIns(4,5)P2 to potassium channel activity regulation.
Researchers at MIT have identified novel receptors in a tiny worm that can modulate nervous system activity. The discovery could lead to new therapeutic targets for psychiatric disorders such as depression and schizophrenia.
Scientists at Duke University Medical Center have identified the molecular pathways triggered by niacin, which could lead to a revival of niacin-based treatments for cholesterol. The discovery suggests that a 'biased ligand' could be developed to target the beneficial effects of niacin while minimizing its flushing side effect.
Researchers at Duke University Medical Center have discovered that beta arrestins, which stop cell signals, also initiate pathways to produce new proteins in virtually all tissues. This new pathway has opened up new avenues for studying protein manufacturing and controlling biological functions.
Scientists have discovered a single protein that can inhibit aging, which could hold implications for human longevity and treatment of diseases. The technique used to make the inhibiting proteins opens the possibility of developing new therapeutics.
Researchers found that a loose connection between hormone and GPCR allows for stronger signal activation, potentially leading to more effective drug therapies. The study used thyrotropin-releasing hormone (TRH) as a model and suggests that a similar approach could be applied to other hormone-GPCR reactions.
Scientists at the University of Rochester Medical Center have found a mechanism to modify the effects of major drug class, potentially leading to better control of pain relief, inflammation, and heart disease. The new drugs aim to influence related signaling on the inside of cells, rather than on the outside.
Researchers have discovered a potential mechanism to eliminate the unwanted taste of artificial sweeteners by inhibiting the natural termination of taste-receptor signals. By targeting specific receptors and kinases, scientists hope to develop more effective and pleasant sugar substitutes.
Researchers develop soluble mimics of GPCRs to study their interactions with G-proteins, potentially leading to new drugs for various medical conditions. The technology could also be used to screen for drugs that block malfunctioning GPCRs.
A study found that mice deficient in RGS2, a regulatory protein, exhibited persistent vessel constriction and strongly hypertensive effects. This suggests that abnormally prolonged GPCR signaling may contribute to the onset of hypertension.
Researchers at Allelix Biopharmaceuticals Inc. have successfully cloned the GLP-2 receptor, which plays a crucial role in intestinal growth and nutrient absorption. The discovery provides valuable information on the specificity and action of GLP-2, a potential therapy for gastrointestinal disorders such as short bowel syndrome.